DanielJGeorgeMD

PubMed

• 31 citations
  Development of a Novel c-MET-Based CTC Detection Platform.
  Tian Zhang, Rengasamy Boominathan, Brad Foulk, Chandra Rao, Gabor Kemeny
  Molecular Cancer Research. 2016-06-01
• 53 citations
  Prostate cancer. Clinical practice guidelines in oncology.
  James Mohler, Richard J Babaian, Robert R Bahnson, Barry Boston, Anthony D'Amico
  Journal of the National Comprehensive Cancer Network. 2007-08-01
• 80 citations
  Men Older Than 70 Years Have Higher Risk Prostate Cancer and Poorer Survival in the Early and Late Prostate Specific Antigen Eras
  Leon Sun, Arthur A. Caire, Cary N. Robertson, Daniel J. George, Thomas J. Polascik
  The Journal of Urology. 2009-11-01

Journal Articles

• Survuval Outcomes of Sipuleucel-T Phase 3 Studies: Impact of Control Arm Cross-over to Salvage Immunotherapy  
  George DJ, Nabhan C, DeVries T, Whitmore JB, Gomella LG, Cancer Immunol Res, 1/5/2016
• Clinical Trial Participants with Metastatic Renal Cell Carcinoma Differ From Patients treated in Real-World Practice  
  Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hersch BR, J Oncol Pract, 1/1/2016
• Trial Design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3  
  Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussai..., J Clin Oncol, 1/1/2016
• The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: Res...  
  Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Sadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ; for the Alliance for Clinical Trials i..., Cancer, 1/31/2013
• Preopertative Enoxaparin vs Postoperative Semuloparin Thromboprophylaxis in Major Abdominal Surgery: A Randomized Controlled Trial  
  Kakkar AK, Agnelli G, Fisher W, George D, Lassen MR, Mismetti P, Mouret P, Murphy J, Lawson F, Turpie AG, for the SAVE-ABDO Investigators, Ann Surg, 1/26/2013
• “Real World” treatment of metastatic renal cell carcinoma in a joint community – academic cohort: Progression-free survival over three lines of therapy  
  Harrison MR, George DJ, Walker MS, Chen C, Korytowsky B, Kirkendall DT, Stepanski EJ, Abernethy AP, Clin Genitourin Cancer, 1/12/2013
• A Phase II trial of Temsirolimus in men with castration-resistant metastatic prostate cancer  
  Armstrong AJ, Shen T, Halabi S, Kemeny G, Bitting RL, Kartcheske P, Embree E, Morris K, Winters C, Jaffe T, Fleming M, George DJ, Clin Genitourin Cancer, 1/3/2013
• Metastatic CRPC: a cross-sectional landscape of the disease and treatments  
  George D, Urology, 1/1/2013
• Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure  
  Autio KA, Bennett AV, Jia X, Fruscione M, Beer TM, George DJ, Carducci MA, Logothetis CJ, Kane RC, Sit L, Rogak L, Morris MJ, Scher HI, Basch EM, J Oncol Pract, 1/1/2013
• Recent Advances in the Management of Castration-Resistant Prostate Cancer  
  George DJ, Cl Advances in Hematology & Oncology, 1/1/2013
• Novel immunotherapeutic strategies in development for renal cell carcinoma  
  Inman BA, Harrison MR, George DJ, Eur Urol, 1/12/2012
• A phase II study of lapatinib, a dual EGFR and HER-w tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer  
  Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, Morris K, Watkins CP, George DJ, Urol Oncol, 1/9/2011
• Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) resistance in metastatic renal cell carcinoma (mRCC): Possible mechanisms and clin...  
  Harrison MR and George DJ, Eur J Clin Med Oncol, 1/1/2011
• Increased mobilization of circulating endothelial progenitors in von Hippel-Landau disease and renal cell carcinoma  
  Bhatt RS, Zurita AJ, O’Neill A, Norden-Zfone A, Zhang L, Wu HK, Wen PY, George D, Sukhatme VP, Atkins MB, Heymach JV, Br J Cancer, 1/1/2011
• Is tumor response important for renal carcinoma?  
  Inman B, George DJ, Eur Urol, 1/1/2011
• A pharmacodynamic study of repamycin in men with intermediate-to-high risk localized prostate cancer  
  Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, George DJ, Gur..., Clin Cancer Res, 1/1/2010
• NCCN clinical practice guidelines in oncology: prostate cancer  
  Mohler J, Bahnson RR, Boston B, Busby JE, D’Amico A, Eastham JA, Enke CA, George D, Pow-Sang JM, Roach M 3rd, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twar..., J Natl Compr Canc Netw, 1/1/2010
• Bevacizumab and everolimus in renal cancer: a rational way forward  
  Stadler WM, Phillips G, George DJ, Halabi S, Small E, J Clin Oncol, 1/1/2010
• Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research  
  Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, slovin SF, Ryan C, Logothetis C, Scher HI, Clin Genitourin Cancer, 1/1/2009
• Histone deacetylase inhibitor panobinostat induces clinic responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma  
  Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, Mita M, Beck J, Burris H, Ryan G, Atadja P, Butterfoss D, Dugan M, Culver K, Johnstone RW, Prince HM, Clin Cancer Res, 1/1/2008
• Cell Signaling modifiers in prostate cancer  
  Chen FL, Armstrong AJ, George DJ, Cancer Journal, 1/1/2008
• Clinical endpoints for drug development in prostate cancer  
  Ramiah V, George DJ, Armstrong AJ, Curr Opin Urol, 1/1/2008
• New drug development in metastatic prostate cancer  
  Armstrong AJ, George DJ, Urol Oncol, 1/1/2008
• Antitumor activity and biomarker analysis of Sunitinib in patients with Bevacizumab-Refractory Metastatic Renal Cell Carcinoma  
  Rini BI, Michaelson D, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ, Rini BI, Michaelson D, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ, 1/1/2008
• Satraplatin in the treatment of hormone-refractory metastatic prostate cancer  
  Armstrong, AJ, George DJ, Ther Clin Risk Manag, 1/1/2007
• Join now to see all

Books/Book Chapters

• Management of Castration Resistant Prostate Cancer 
  Chapter: Angiogenesis Inhibition in Castration-Resistant Prostate Cancer 
  George D, Kelly William, Mitchell AEditors: Fred Saad and Mario A Eisenberger.2014
• Oxford-American Handbook of Oncology 
  Chapter: Renal Cell Carcinoma 
  Mendiratta P, George DJ, Armstrong AJEditors: Gary Lyman.2009
• Renal Cell Carcinoma 
  Chapter: mTOR pathway biology in renal cell carcinoma 
  Kim W, Armstrong AJ, George DJEditors: Brian Rini and Steven Campbell.BC Decker, Inc., Ontario, CanadaEdition 1st,2009
• Oxford-American Handbook of Oncology 
  Chapter: Genitourinary cancers I: Renal, bladder, ureter, penile carcinomas 
  Mendiratta P, Armstrong A, Febbo P, George, DEditors: Gary H Lyman with Jim Cassidy Donald Bissett, Ray A J Spence and Miranda Payne.2009
• Diseases of the prostate 
  Chapter: Novel tumor-directed therapeutic strategies for hormone-refractory prostate cancer 
  George DJ, Wilding GEditors: Kantoff PW, D’Amico AV, Carroll P.Lippincott-Raven, Philadelphia, PA2000
• Brenner and Rector’s The Kidney 
  Page 1895 - 1923Jonasch E, George DJ, Atkins MAElsevier Science Ltd, London, UKEdition 7th,
• Progress in Oncogene Research 
  Chapter: Von Hippel-Lindau Gene Pathway and Tyrosine Kinase Inhibitors in Renal Cell Carcinoma 
  Potti A, and George, DJ
• Update on Cancer Therapeutics 
  Chapter: Angiogenesis Inhibitors in Clinical Oncology 
  Moore C and George, DJ
• Contemporary Cancer Research: Prostate Cancer: Biology, Genetics, and the New Therapeutics 
  Chapter: Intercellular Targets of Prostate Cancer 
  Whang YE and George, DJEdition 2nd,
• Join now to see all

Abstracts/Posters

• A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer
  Armstrong AJ, Shen T, Halabi S, Kemeny G, Bitting RL, Kartcheske P, Embree E, Morris K, Winters C, Jaffe T, Fleming MT, George DJ, Journal of Clinical Oncology, Genitourinary Cancers Symposium, 1/1/2013
• Isolation of circulating tumor cells using a novel EMT-based capture method
  Bitting RL, Boominathan R, Rao C, Embree E, George DJ, Connelly MC, Kemeny G, Garcia-Blanco M, Armstrong AJ, Journal of Clinical Oncology, 1/1/2012
• A randomized, controlled phase III global trial comparing sipuleucel-T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastat...
  Fizazi K, Powles T, George DJ, Poehlein CH, ASCO Annual Meeting, Journal of Clinical Oncology, 1/1/2011
• Subsequent treatment with APC8015F and its effect on survival in the control arm of phase III sipuleucel-t studies
  George DJ, Nabhan C, Gomella LG, Whitmore JB, Frohlich MW, Genitourinary Cancers Symposium, General Poster Session B: Prostate Cancer, Journal of Clinical Oncology, 1/1/2011
• Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC)
  Halabi S, Kelly WK, George DJ, Morris MJ, Kaplan EB, Small EJ, Genitourinary Cancers Symposium, General Poster Session B: Prostate Cancer, Journal of Clinical Oncology, 1/1/2011
• Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer...
  George DJ, Halabi S, Zurita AJ, Creel P, Mundy K, Turnbull JD, Yenser Wood SE, Armstrong AJ, Varley RJ, Madden J, Moul JW, ASCO Annual Meeting, Genitourinary (Prostate) Cancer, Journal of Clinical Oncology, 1/1/2011
• The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolish (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study
  Agnelli G, George DJ, Fisher W, Kakkar AK, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Turpie AGG, ASCO Annual Meeting, Genitourinary (Prostate) Cancer, Journal of Clinical Oncology, 1/1/2011
• Post-progression treatment with APC8015F may have prolonged survival of subjects in the control arm of sipuleucel-T phase II studies
  Gomella LG, Nabhan C, Whitmore JB, Frohlich MW, George DJ, ASCO Annual Meeting, Genitourinary (Prostate) Cancer, Journal of Clinical Oncology, 1/1/2011
• Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase I...
  Armstrong AJ, Kemeny G, Turnbull JD, Chao C, Winters C, Fesko YA, Bradley DA, Halabi S, George DJ, Garcia-Blanco M, ASCO Annual Meeting, Journal of Clinical Oncology, 1/1/2010
• A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with met...
  Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM, Morris MJ, Kantoff P, Monk III JP, Small EJ, ASCO Annual Meeting, Genitourinary Cancer (Prostate), Journal of Clinical Oncology, 1/1/2010
• A Single arm phase Ib study of RAD001 and sunitinib in patients with advanced renal cell carcinoma (RCC)
  Turnbull JD, Armstrong AJ, Morris K, Yenser Wood SE, Voyles S, Fesko YA, George DJ, ASCO Annual Meeting, Journal of Clinical Oncology, 1/1/2010
• Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC)
  Armstrong AJ, George DJ, Halabi S, ASCO Annual Meeting, General Poster Session, Genitourinary Cancer, Journal of Clinical Oncology, 1/1/2010
• Evaluation of serum lactate dehydrogenase (LDH) as a predictive biomarker for mTOR inhibition in patients with metastatic renal cell carcinoma (RCC)
  Armstrong AJ, George DJ, Halabi S, Genitourinary Cancers Symposium, Reception and General Poster Session D: Testis, Bladder, Renal and Other GU Neoplasms, 1/1/2010
• A phase I dose-finding trial of intravenous (iv) panobinostat (PAN) with docetaxel (DOC) in patients (pts) with castration-resistant prostate cancer (CRPC)
  Rathkopf DE, Vaishampayan UN, Chi KN, Alumkal JJ, Hotte SJ, George, DJ, Agrawal M, Picus J, Hirawat S, Scher HI, Genitourinary Cancers Symposium, General Poster Session C: Prostate Cancer, 1/1/2010
• Plasticity, stemness, and aggressive behavior in preclinical models and circulating prostate cancer cells: Importance of the transitional phenotypic state to lethal c...
  Armstrong AJ, Oltean S, Marengo M, Chen L, Kemeny G, Herold CI, Marcom PK, George DJ, Garcia-Blanco M, Genitourinary Cancers Symposium, General Poster Session C: Prostate Cancer, 1/1/2010
• Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens
  Armstrong AJ, Halabi S, Tannock IF, George DJ, DeWit R, Eisenberger M, Genitourinary Cancers Symposium, General Poster Session C: Prostate Cancer, 1/1/2009
• Pharmacodynamic (PD) study of pre-prostatectomy repamycin in men with advanced localized prostate cancer (PC): Preliminary results of a Department of Defense Prostate...
  Armstrong AJ, Rudek M, Jimeno A, Wood DP, Gurganus R, Partin A, Febbo PG, George DJ, Albadine R, Netto G, Carducci M, Genitourinary Cancers Symposium, General Poster Session C: Prostate Cancer, 1/1/2009
• Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC) – preliminary results
  George DJ, Liu G, Wilding G, Hutson TE, Chen I, Maneval E Chow, Logothetis CJ, Zurita AJ, ASCO Annual Meeting, Genitourinary Cancer, Journal of Clinical Oncology, 1/1/2008
• Phase II Trial of lapatinib in hormone refractory prostate cancer
  Whang YE, Moore CN, Armstrong AJ, Rathmell W, Godley PA, Crane JM, Grigson G, Morris K, Watkins CP, George DJ, Genitourinary Cancers Symposium, General Poster Session C: Prostate Cancer, 1/1/2008
• A Phase I dose escalation study of oral panobinostat (LBH589) alone and in combination with IV docetaxel (Doc) and oral prednisone in castration-resistant prostate can...
  Rathkopf DE, Wong BY, Ross RW, George DJ, Picus J, Sawyers CL, Chen Y, Tanaka E, Yang W, Culver KW, Scher HI, Genitourinary Cancers Symposium, General Poster Session C: Prostate Cancer, 1/1/2008
• A Phase II study of RAD001 in men with hormone-refractory metastatic prostate cancer (HRPC)
  George DJ, Armstrong AJ, Creel P, Morris K, Madden J, Turnbull J, Dewhirst M, Major N, Febbo PG, Genitourinary Cancers Symposium, General Poster Session C: Prostate Cancer, 1/1/2008
• The impact of gender and age in renal cell carcinoma: age is an independent prognostic factor in women but no men
  Pantuck AJ, Klatte T, Patard J, Cindolo L, De La Taille A, Tostain J, Ferriere J, Pfrister C, Kabbinavar FF, Belldegrun AS, George DJ, ASCO Annual Meeting, Genitourinary Cancer, Journal of Clinical Oncology, 1/1/2008
• A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC)
  Rathkopf DE, Wong BY, Ross RW, George DJ, Picus J, Tanaka E, Chen Y, Atadja P, Yang W, Culver KW, Scher HI, ASCO Annual Meeting, Genitourinary Cancer, Journal of Clinical Oncology, 1/1/2008
• Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results of two phase II trials and prognostic factor analysis for survival
  Rosenberg JE, Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Bukowski RM, George DJ, Kim ST, Baum CM, Wilding G, Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 1/1/2007
• Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients
  Speca, J. C., Mears, A. L., Creel, P. A., Yenser, S. E., Bendell, J. C., Morse, M. A., Hurwitz, H. I., Armstrong, A. J., George, D. J., Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 1/1/2007
• Join now to see all

Lectures

• Extending Survival in Kidney Cancer: The New Reality 
  Chicago, IL - 1/1/2016
• Prostate, Colon and smoking cessation 
  Durham, NC - 1/1/2016
• Duke Cancer Institute’s approach to prostate cancer screening and implementation of an active surveillance program: Doing the right thing for our patients 
  Durham, NC - 1/1/2015
• Front Line Therapy – When and What to Start 
  Chapel Hill, NC - 1/1/2015
• Drugs for Metastatic Disease 
  Chapel Hill, NC - 1/1/2013
• GU Malignancies: Renal Cell Cancer 
  1/1/2013
• Optimization of RCC Therapy 
  New York, NY - 1/20/2011
• The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolish (VTE) in cancer patients receiving chemotherapy: SAVE ONCO study 
  1/6/2011
• Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer... 
  1/5/2011
• The Great Debate: Is there a best treatment strategy for GU Malignancies? 
  1/2/2011
• Prostate cancer 
  1/1/2011
• Mechanisms of Resistance to RCC Therapy 
  Chicago, IL - 1/1/2011
• Multidisciplinary Assessments in Advanced RCC: Translating Evidence into Practice 
  Washington, DC, 2011; Union, NJ, 2011 - 1/1/2011
• Updates in the Management of Advanced Renal Cancer Carcinoma 
  1/1/2011
• Advanced Prostate Cancer Webcast 
  1/1/2011
• Update in the Biology and Treatment of Metastatic CRPC 
  Durham, NC - 1/1/2011
• Prostate Cancer: Current Treatment and Potential Imaging 
  Washington, DC - 1/1/2010
• Updates in RCC Research 
  Miami, FL - 1/1/2010
• Image-guided bone marrow biopsies in prostate cancer: The PCCTC Experience 
  Falls Church, VA - 1/1/2010
• Novel Assessments of mTOR inhibition in prostate cancer 
  Durham, NC - 1/1/2010
• Updates in Management of Prostate Cancer 
  Las Vegas, NV - 1/1/2009
• Updates in Management of Metastatic Kidney Cancer 
  Las Vegas, NV - 1/1/2009
• Prostate Cancer Team Approach for the New Age 
  Chicago, IL - 1/1/2009
• PSMA Aptamer siRNA Chimeras in Prostate Cancer 
  Durham, NC - 1/1/2008
• Sunitinib in combination with docetaxel and prednisone in patients with mHRPC – preliminary results 
  Chicago, IL - 1/1/2008
• Join now to see all

Other

• Immunotherapy of renal cell carcinoma 
  George D, Jonasch E
  http://www.uptodate.com/contents/immunotherapy-of-renal-cell-carcinoma
  UpToDate, Wolters Kluwer Health - 2012-09-17